BACKGROUND: T-cell prolymphocytic leukemia is an uncommon, aggressive, mature T-cell leukemia characterized by proliferation of T-cell lymphocytes. The recent availability of modern immunophenotypic and molecular tools has allowed a better distinction of this disorder from its B-cell counterpart and other mature T-cell leukemias. PATIENTS AND METHODS: The clinical, pathologic, and cytogenetic features of 57 patients with T-PLL who were evaluated at the Department of Leukemia, M. D. Anderson Cancer Center (MDACC) from 1986 to 2004 were examined. RESULTS: The most common cytogenetic abnormality was inv(14)(q11;q32), which was present in 7 patients. In all 7 patients, this abnormality was associated with other chromosomal aberrations. Patients treated with alemtuzumab at MDACC had a significantly better response rate (P = 0.02) and survival rate (P = 0.002). There were no significant differences in survival based on Tcl-1 expression or different patterns of CD4 and CD8 expression. CONCLUSION: Treatment with alemtuzumab results in higher response rates and a better survival rate in patients with T-cell prolymphocytic leukemia.
BACKGROUND:T-cell prolymphocytic leukemia is an uncommon, aggressive, mature T-cell leukemia characterized by proliferation of T-cell lymphocytes. The recent availability of modern immunophenotypic and molecular tools has allowed a better distinction of this disorder from its B-cell counterpart and other mature T-cell leukemias. PATIENTS AND METHODS: The clinical, pathologic, and cytogenetic features of 57 patients with T-PLL who were evaluated at the Department of Leukemia, M. D. Anderson Cancer Center (MDACC) from 1986 to 2004 were examined. RESULTS: The most common cytogenetic abnormality was inv(14)(q11;q32), which was present in 7 patients. In all 7 patients, this abnormality was associated with other chromosomal aberrations. Patients treated with alemtuzumab at MDACC had a significantly better response rate (P = 0.02) and survival rate (P = 0.002). There were no significant differences in survival based on Tcl-1 expression or different patterns of CD4 and CD8 expression. CONCLUSION: Treatment with alemtuzumab results in higher response rates and a better survival rate in patients with T-cell prolymphocytic leukemia.
Authors: Marco Herling; Kaushali A Patel; Michael A Teitell; Marina Konopleva; Farhad Ravandi; Ryuji Kobayashi; Dan Jones Journal: Blood Date: 2007-09-21 Impact factor: 22.113
Authors: S Oberbeck; A Schrader; K Warner; D Jungherz; G Crispatzu; J von Jan; M Chmielewski; A Ianevski; H H Diebner; P Mayer; A Kondo Ados; L Wahnschaffe; T Braun; T A Müller; P Wagle; A Bouska; T Neumann; S Pützer; L Varghese; N Pflug; M Thelen; J Makalowski; N Riet; H J M Göx; G Rappl; J Altmüller; M Kotrová; T Persigehl; G Hopfinger; M L Hansmann; H Schlößer; S Stilgenbauer; J Dürig; D Mougiakakos; M von Bergwelt-Baildon; I Roeder; S Hartmann; M Hallek; R Moriggl; M Brüggemann; T Aittokallio; J Iqbal; S Newrzela; H Abken; M Herling Journal: Blood Date: 2020-12-10 Impact factor: 22.113
Authors: Suresh Babu Mc; Abhishek Anand; Kuntegowdanahalli C Lakshmaiah; Govind Babu K; Dasappa Lokanatha; Linu Abraham Jacob; D S Madhumathi; Kadabur N Lokesh; A H Rudresha; L K Rajeev; Rajesh Patidar Journal: Int J Hematol Oncol Stem Cell Res Date: 2018-04-01
Authors: Ali Sakhdari; Guilin Tang; Lawrence E Ginsberg; Cheryl F Hirsch-Ginsberg; Carlos E Bueso-Ramos; L Jeffrey Medeiros; Roberto N Miranda Journal: Case Rep Pathol Date: 2019-03-03
Authors: P Jain; E Aoki; M Keating; W G Wierda; S O'Brien; G N Gonzalez; A Ferrajoli; N Jain; P A Thompson; E Jabbour; R Kanagal-Shamanna; S Pierce; A Alousi; C Hosing; I Khouri; Z Estrov; J Cortes; H Kantarjian; F Ravandi; T M Kadia Journal: Ann Oncol Date: 2017-07-01 Impact factor: 32.976